Ichthyosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ichthyosis pipeline constitutes 4+ key companies continuously working towards developing 6+ Ichthyosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ichthyosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ichthyosis Market.

The Ichthyosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ichthyosis Pipeline Report: https://www.delveinsight.com/sample-request/ichthyosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ichthyosis treatment therapies with a considerable amount of success over the years.
• Ichthyosis companies working in the treatment market are Timber Pharmaceuticals, Krystal Biotech, GSK, Janssen Scientific, Patagonia Pharma, Crown Laboratories, Inc, and others, are developing therapies for the Ichthyosis treatment
• Emerging Ichthyosis therapies in the different phases of clinical trials are- TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others are expected to have a significant impact on the Ichthyosis market in the coming years.
• In January 2025, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has reported additional positive interim data from its ongoing clinical study for Netherton Syndrome. The company previously shared promising results from the first subject dosed twice daily with QRX003 at the six-week midpoint. Now, Quoin has released clinical data following the full 12-week treatment period, highlighting significant improvements across all measured clinical endpoints. The observed results further support the potential efficacy of QRX003 in treating Netherton Syndrome, reinforcing its role as a promising therapeutic candidate for this rare condition.
• In August 2024, Timber Pharmaceuticals Inc., a LEO Pharma company, has released findings from the randomized, double-blind 12-week phase of the ASCEND trial. The study did not demonstrate a statistically significant difference in response rates between patients treated with TMB-001 and those receiving the vehicle after 12 weeks. ASCEND is a Phase 3 clinical trial evaluating TMB-001, an investigational topical isotretinoin formulation, as a potential treatment for moderate to severe congenital ichthyosis.

Ichthyosis Overview
Ichthyosis is a group of rare genetic skin disorders characterized by dry, scaly, and thickened skin that resembles fish scales. The condition results from abnormal skin cell shedding or production, leading to a buildup of rough, flaky skin. It can range from mild forms, such as ichthyosis vulgaris, to severe types, like lamellar ichthyosis or harlequin ichthyosis. Symptoms often include persistent dryness, scaling, itching, and sometimes painful cracks in the skin. While there is no cure, treatments such as moisturizers, keratolytic agents, and retinoids help manage symptoms and improve skin appearance.

Get a Free Sample PDF Report to know more about Ichthyosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ichthyosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Ichthyosis Drugs Under Different Phases of Clinical Development Include:
• TMB-001: Timber Pharmaceuticals
• KB105: Krystal Biotech
• Liarozole: GSK
• TMB-001: Timber Pharmcecuticals
• Ustekinumab: Janssen Scientific
• PAT-001: Patagonia Pharma
• Isotretinoin: Timber Pharmcuticals
• 146-9251: Crown Laboratories, Inc

Ichthyosis Route of Administration
Ichthyosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Ichthyosis Molecule Type
Ichthyosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Ichthyosis Pipeline Therapeutics Assessment
• Ichthyosis Assessment by Product Type
• Ichthyosis By Stage and Product Type
• Ichthyosis Assessment by Route of Administration
• Ichthyosis By Stage and Route of Administration
• Ichthyosis Assessment by Molecule Type
• Ichthyosis by Stage and Molecule Type

DelveInsight's Ichthyosis Report covers around 6+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ichthyosis product details are provided in the report. Download the Ichthyosis pipeline report to learn more about the emerging Ichthyosis therapies at:
https://www.delveinsight.com/sample-request/ichthyosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Ichthyosis Therapeutics Market include:
Key companies developing therapies for Ichthyosis are - GSK plc, LEO Pharma A/S, Galderma (Nestle), Mayne Pharma Group, Krystal Biotech, Inc, Johnson & Johnson Services, Inc, AbbVie Inc., Regeneron Pharma, and others.

Ichthyosis Pipeline Analysis:
The Ichthyosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ichthyosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ichthyosis Treatment.
• Ichthyosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ichthyosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ichthyosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ichthyosis drugs and therapies-
https://www.delveinsight.com/sample-request/ichthyosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ichthyosis Pipeline Market Drivers
• Ongoing Search for Cure - Along with clinical trials in Ichthyosis, various institute/ organization/ and groups are conducting research to find cure for this disease.
• Various Organization and Foundation Support - Organizations and government level support has aided in further development of angleman syndrome treatment

Ichthyosis Pipeline Market Barriers
• However, Lack of treatment protocols, Research funding, Biomarker research, Integrative and novel therapies, and other factors are creating obstacles in the Ichthyosis Market growth.

Scope of Ichthyosis Pipeline Drug Insight
• Coverage: Global
• Key Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Janssen Scientific, Patagonia Pharma, Crown Laboratories, Inc, and others
• Key Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others
• Ichthyosis Therapeutic Assessment: Ichthyosis current marketed and Ichthyosis emerging therapies
• Ichthyosis Market Dynamics: Ichthyosis market drivers and Ichthyosis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.